Novo Nordisk Faces Sales Growth Slowdown Amid Supply Challenges

Pharmaceutical giant Novo Nordisk, renowned for its diabetes and obesity treatments, is bracing for a slowdown in sales growth due to persistent supply chain constraints. The Danish company reported that the soaring demand for its weight-loss drugs, particularly those featuring the active ingredient semaglutide, is encountering significant hurdles in production and distribution.

Continue reading